SAVE

Vascular anomalies, including lymphatic, venous, arteriovenous malformations, and Kaposiform hemangioendotheliomas are rare and serious congenital disorders that significantly impact quality of life and can be life threatening. Current treatments are limited. Sirolimus, though effective, is only available off label and in formulations that frequently cause major side effects and safety concerns, particularly for children and those with complex medical needs. These side effects can undermine treatment adherence, and patients might even be forced to stop their treatment with sirolimus, leading to a relapse of their underlying condition. This situation underscores the urgent need for a safer, more tolerable therapeutic solution that supports both patient safety and long-term compliance — an opportunity SAVE is positioned to address.

SAVE, is led by medical experts of the expert centre for vascular anomalies at the Radboudumc and supported by ApotheekA15 BV to market the product. We are developing and registering a new, innovative sirolimus formulation designed to eliminate side effects, avoid drug interactions, provide consistent and safe dosing for all ages. A formulation patent is under development. Our goal is to transform care by reducing pain, infections, thrombosis risk, enabling better outcomes and quality of life for patients with vascular anomalies across Europe and beyond. Our centre for vascular anomalies is among the largest in Europe. The multidisciplinary medical professionals of the Radboudumc, involved in SAVE are recognised as leading (inter)national experts in the field. As being key opinion leaders in the field, recruitment and subsequently market uptake will be rapid facilitated.

* SAVE stands for Sirolimus Available for Vascular anomalies in Europe